2nd IMMUNO-ONCOLOGY SOCIETY OF INDIA ANNUAL CONGRESS 2020
My greetings and well wishes to all of you for your good health and inspiring work in cancer and community care.
On the behalf of the Immuno-oncology Society of India(I-OSI), I am pleased to welcome you for the annual national virtual conference. This will be three days virtual programme from October 30 to 31 (4 pm-9 pm India Standard Time) and Nov 1, 2020 (9 am to 1 pm IST).
I-OSI has been the leader in promoting tumor immunology and advancing cancer immunotherapy education, information and research in India. Our annual conference will highlight the current state of immuno-oncology for cancer care professionals with emphasis on current research, utilization trends, and advances in immunotherapies. Hence, the theme of this year’s conference is Immuno-Oncology towards 2021: Reboot, Resolve and Evolve.
The 3 days congress is designed to provide scientists and clinicians with a common interest in immuno-oncology to interact with the current and future leaders from all around the world. These leaders would provide insights and perspectives into present and future issues, challenges, and improvements needed for immunotherapy to be integrated into the mainstream cancer treatment.
With 3876 agents and 469 targets in 2019, the recent white paper points to the likelihood of further expansion of immunotherapy to treat more patients in the future. Factors that support this belief include the emergence of checkpoint inhibitors as feasible therapies in a variety of adjuvant and neoadjuvant settings, an increase in utilization of immuno-oncology therapies as part of combination regimens or in sequence with chemotherapy or targeted agents, and the increase of immuno-oncology delivery in the community.
As the paradigm in cancer treatment changes, I-OSI Annual Meeting continues to lead and drive the numerous advances our field is making. Additionally, I-OSICON will also try to address survivorship needs, which includes unpredictable and delayed immune-related adverse events, follow-up, and psychosocial support.
I also request you to register (complimentary) for this conference and be a member of I-OSI.
Together we have and we will fight all the uncertainties to give the best care to our patients.
Join I-SOI, Join us!
Dr Jyoti Bajpai,
Organizing Secretory, I-OSICON- 2
Founder General Secretary: Immuno-Oncology Society of India (I-OSI)
Professor, Medical Oncology, Tata Memorial Centre, Mumbai, India